At ProBiotix Health, we’re committed to accelerating scientifically validated, probiotic-based product solutions for the support and improvement of human health. At the heart of our mission lies a unique approach; we identify groundbreaking probiotic strains, validate their benefits through solid science, and take these strains to market as effective finished probiotic-based products for improved human health across the globe.
Our dedication to these three key areas sets us apart, supporting our role as pioneers in the probiotic field and at the forefront of advancements in global health. By using innovative technology, conducting research and development, and demonstrating efficacy through clinical trials, it is our mission to discover new ways to help consumers improve and lengthen their health span through probiotic advancements.
For us, it’s not just about adding years to life, but also life to years.
1. Identification
Identification and evolution of groundbreaking probiotic strains targeting lifestyle conditions that are prevalent globally in healthy ageing.
According to research from the National Heart, Lung, and Blood Institute and NI Direct, 1 in 31 US adults and 1 in 4 in the UK2 have metabolic syndrome, which raises the risk of coronary heart disease, diabetes, and stroke. Yet, with scientific advancements in cardiometabolic health, the life sciences industry is collectively discovering and identifying natural ingredients—like probiotic strains—to improve human health.
The ProBiotix team is working towards the same goal — to prioritise the identification and evolution of groundbreaking probiotic strains. Scientists and microbiologists by nature and by trade, our team discovered a ‘1 in 4000’ probiotic. Using our proprietary ProScreen technology platform, we identified LPLDL® as the most superior probiotic for cardiometabolic health out of a candidate group of 4,000 potential strains.
This IP protect probiotic strain, was identified due to its exceptional mechanism of action that influences bile salt hydrolysis and its ability to survive the harsh conditions of the intestines. Through rigorous testing, we found that LPLDL® decreases bile salt reabsorption, increases cholesterol uptake from the blood into the liver to replenish bile acid levels, and effectively decreases cholesterol concentration in the blood.
2. Validation
Scientific validation ensuring our probiotic strains stand on a solid foundation of validated safety and efficacy for human health.
To advance global health, we needed to ensure that our probiotic strains are not only effective but safe to use. By working with world-renowned research partners, including academic institutions like the University of Reading, University of Roehampton and University of Pavia, we aim to validate the identified probiotic strains’ efficacy through clinical trials.
Since our discovery, LPLDL®’s cardiometabolic health-supporting effects have been published in multiple human clinical trials. Results of our scientific studies demonstrated that LPLDL® was shown to be completely safe and well-tolerated. Due to its identified mechanism of action, it was also proven to reduce total cholesterol and LDL cholesterol while lowering systolic and diastolic blood pressure. You can read more on the statistically significant results of our scientific studies here.
In addition to these human studies, LPLDL® is able to utilise structure function claims* for US consumer packaging and promotional materials. Under structure function claims, LPLDL® ‘helps maintain cholesterol levels already in the normal range’, ‘supports normal LDL and HDL cholesterol levels’, has a ‘positive effect on cholesterol levels within the normal range’ and ‘benefits long term cardiovascular health’.
The ProBiotix team continues to seek recognition from global health authorities by validating safety, efficacy and credibility of LPLDL and its finished formulations via scientific studies.
3. Commercialisation
Developing advanced probiotic-based product formulations targeted for cardiometabolic health, ensuring measurable health benefits.
By keeping abreast of consumer trends, we have the in-house capabilities to help you commercialise food supplements, OTC pharmaceutical formulations and optimised dosage formats.
At ProBiotix Health, we are committed to developing innovative, probiotic-based formulations that incorporate identified and scientifically validated strains. With over 120 years of combined experience in the probiotic market, our management team excels in new product innovation and the seamless transition from concept to commercialisation. This deep expertise equips the company to offer comprehensive, ready-to-market turn-key solutions that effectively address consumer health needs across the globe.
Our award-winning probiotic, LPLDL®, features in our product portfolio, providing turn-key supplements for rebranding by organisations. Offered in a range of different formats, including instant melt stick packs, multi-layered tablets, and capsules, YourBiotix products containing LPLDL® have five individual formulations to meet cardiometabolic health requirements to support cholesterol levels, vascular health, and blood pressure.
Ensuring Consumer Health Together – Lead the Way in Supplement Innovation
The strategic integration of these three cornerstones enables our partners to focus on their core competencies – marketing and selling these advanced probiotic solutions. Together, we can deliver advanced scientific formulations that are validated through clinical trials to support consumers in living much longer and, more importantly, healthier lives. By collaborating with ProBiotix Health, businesses are assured that every aspect of product development, from pioneering scientific research to manufacturing excellence, is thoroughly managed.
With cardiometabolic health issues on the rise and the probiotics market expected to continue its rapid growth, the commercial opportunity and consumer need for finished format probiotic solutions is only increasing. Together, with ProBiotix Health, we can lead the way in supplement innovation and enhance consumer health worldwide.
* These statements have not been evaluated by the Food and Drug Administration. The product is not intended to diagnose, treat, cure, or prevent any disease.
References
1. NIH, May 2022
2. NI Direct, accessed May 2024
3. EFSA Journal (2009). 7(9):1222
